Optic tract meningioma

Summary

Optic tract meningioma (MONDO:0024648) is a disease. A subtype of visual pathway disorder — broader associated-gene and molecular evidence is on the parent page (see Disease family below).

Clinical features

No curated clinical features (Orphanet) for this disease.

Identifiers

Disease identifiers

Field	Value
Canonical name	optic tract meningioma
Mondo ID	MONDO:0024648
NCIT	C5587
UMLS	C1336972
MedGen	234991
GARD	0025444
Anatomy (UBERON)	UBERON:0001908
Is cancer (heuristic)	no

Also known as: meningioma (disease) of optic tract · meningioma of optic tract · meningioma of the optic tract · meningioma of the visual pathway · meningioma of visual pathway · optic tract meningioma · optic tract meningioma (disease) · visual pathway meningioma

Disease family

This is a subtype of visual pathway disorder. Genetic, therapeutic, and trial evidence is largely curated at the broader-term level — see the parent page for the associated-gene cohort and molecular evidence.

Classification path: disease › human disease › disease by body system or component › nervous system disorder › central nervous system disorder › brain disorder › visual pathway disorder › optic tract meningioma

Related subtypes (4): retinal nerve fiber layer disorder, visual cortex disorder, coloboma of optic nerve, optic pathway glioma

Subtypes (2): anterior optic tract meningioma, bilateral meningioma of optic nerve

Genetics & variants

GWAS landscape

No GWAS associations recorded — common-variant (GWAS) studies don’t cover this disease (typical for Mendelian / rare diseases). See the curated gene cohort and Mendelian overlap below.

Variant details and genetic-evidence tiers

No tiered GWAS variants or ClinVar records for this disease.

Genes & proteins

No associated-gene cohort resolved for this disease. Atlas builds the molecular and therapeutic sections — associated genes, protein families, druggability, pathways, interactions, and drug associations — by aggregating over a disease’s associated genes (resolved via GWAS / GenCC / ClinVar / CIViC), and none resolved here. This is expected for antibody-mediated, autoimmune, or otherwise non-gene-defined conditions; the curated evidence for this disease is its clinical features, GWAS susceptibility, and clinical trials (above).

Function

No pathway enrichment — requires an associated-gene cohort.

Therapeutics

No druggable-target or therapeutic data for this disease’s cohort.

Clinical trials & evidence

Clinical trials

Clinical trials: 0.